BioImagene appoints new VP of sales of marketing & releases Virtuoso

2 recent press releases from BioImagene in advance of USCAP meeting next week.  Michael Descour over at Virchow's Pixel also has some interesting comments about the exhibitor floor at USCAP 2009. Abbreviated press releases below:

BioImagene, the leading provider of innovative digital pathology solutions, today announced the appointment of Doug Sweet as Vice President of Sales and Marketing. Mr. Sweet has more than 30 years of experience in business development, marketing and sales in the Diagnostic Industry – Clinical and Anatomic Pathology, Life Science and BioPharma.

Dr. Ajit Singh, CEO BioImagene commented, “We are extremely pleased that Doug has joined the BioImagene team.  As the pathology industry transitions into a digital era, Doug’s experience will be a valuable asset in further strengthening our market leadership. His proven success in launching over a dozen diagnostic products in his career will help us as we roll out the industry’s most comprehensive line of digital pathology solutions.”

For the last three years, Doug served as Vice President of Marketing and Sales for Celerus Diagnostics where he created a Sales, Marketing and Customer Care team to launch a revolutionary IHC system.  Prior to joining Celerus, Doug has held various executive positions in Business Development and Sales/Marketing at  Ventana Medical Systems, Dako Corporation, BioPath Corporation, Molecular Devices, as well as Syva, an early stage division of Syntex Corporation.  Doug has also worked at New England Nuclear and Corning Medical and served as an advisor for Agilent Technologies, Exagen Diagnostics, HistoRx, BioImagene, Pathworks Diagnostics and Spring BioSystems.

“I am privileged to be joining BioImagene, at this point in the company’s evolution.  The company is poised for tremendous growth with their unique solutions and business model,” commented Mr. Sweet.

Mr. Sweet holds a BS in Biology from the University of Oregon and an MBA from the Presidential/Key Executive program at Pepperdine University.

————————————————————————————————————————-

BioImagene, the leading provider of innovative digital pathology solutions announced the launch of Virtuoso – the next generation digital pathology solution. 

Virtuoso is a comprehensive suite of web-based software applications that work with BioImagene’s iScanTM slide scanners to provide an end-to-end workflow solution.  It is a Role-Based system and it enables the various stakeholders, or roles  – Pathologist, Histo-technologist, Lab Administrator, Clinician, etc  – to improve the efficiency and quality of the various steps in the Anatomical Pathology workflow. It allows the user to scan glass slides, and then perform a wide range of functions – view, manage, manipulate, analyze, report and collaborate – in the digital form.

Dr Ajit Singh, CEO BioImagene commented, “Pathology workflow is complex. One needs a software application that is adept at orchestrating the various tasks performed by multiple roles in this complex environment – seamlessly and with high quality. That’s what Virtuoso does. The analogy to musical concert is compelling.”  Dr. Singh added, “Virtuoso will accelerate the move of pathology into the digital age, ultimately becoming a key enabler for personalized medicine.” 

Maryanne Amato, Director of GenPath services at BioReference Laboratories (NASDAQ: BRLI), an existing BioImagene customer said, “We welcome BioImagene’s Virtuoso solution and look forward to deploying the newly designed software to our customers. Laboratories today are information companies. We need all the support we can get to facilitate the flow of information to the physician in order to ultimately improve patient care.  BioImagene's digital pathology solutions give us the potential to rapidly provide information in a digital format that is more useful to our physician customers.”

The Virtuoso solution includes distinctly enhanced features in the user interface, slide navigation tools, LIS integration, reporting and includes a comprehensive menu of validated image analysis IHC protocols. This will strengthen Bioimagene’s dominant market position.